全文获取类型
收费全文 | 4183篇 |
免费 | 222篇 |
国内免费 | 17篇 |
专业分类
耳鼻咽喉 | 30篇 |
儿科学 | 115篇 |
妇产科学 | 62篇 |
基础医学 | 511篇 |
口腔科学 | 189篇 |
临床医学 | 350篇 |
内科学 | 1047篇 |
皮肤病学 | 55篇 |
神经病学 | 351篇 |
特种医学 | 81篇 |
外国民族医学 | 1篇 |
外科学 | 588篇 |
综合类 | 36篇 |
一般理论 | 1篇 |
预防医学 | 367篇 |
眼科学 | 47篇 |
药学 | 209篇 |
中国医学 | 17篇 |
肿瘤学 | 365篇 |
出版年
2023年 | 16篇 |
2022年 | 45篇 |
2021年 | 106篇 |
2020年 | 72篇 |
2019年 | 131篇 |
2018年 | 131篇 |
2017年 | 69篇 |
2016年 | 61篇 |
2015年 | 101篇 |
2014年 | 139篇 |
2013年 | 161篇 |
2012年 | 311篇 |
2011年 | 313篇 |
2010年 | 157篇 |
2009年 | 153篇 |
2008年 | 288篇 |
2007年 | 279篇 |
2006年 | 301篇 |
2005年 | 291篇 |
2004年 | 259篇 |
2003年 | 219篇 |
2002年 | 211篇 |
2001年 | 41篇 |
2000年 | 54篇 |
1999年 | 50篇 |
1998年 | 39篇 |
1997年 | 33篇 |
1996年 | 25篇 |
1995年 | 33篇 |
1994年 | 21篇 |
1993年 | 26篇 |
1992年 | 28篇 |
1991年 | 20篇 |
1990年 | 20篇 |
1989年 | 21篇 |
1988年 | 16篇 |
1987年 | 17篇 |
1986年 | 13篇 |
1985年 | 9篇 |
1984年 | 15篇 |
1983年 | 17篇 |
1982年 | 17篇 |
1981年 | 16篇 |
1980年 | 10篇 |
1979年 | 9篇 |
1976年 | 8篇 |
1975年 | 7篇 |
1974年 | 4篇 |
1973年 | 10篇 |
1971年 | 4篇 |
排序方式: 共有4422条查询结果,搜索用时 15 毫秒
1.
Quality of life in stroke survivor–caregiver dyads: a new conceptual framework and longitudinal study protocol 下载免费PDF全文
2.
Exacerbation of Partial Seizures and Onset of Nonepileptic Myoclonus with Carbamazepine 总被引:4,自引:3,他引:1
A child had two to three generalized tonic-clonic (GTC) seizures per week unresponsive to phenobarbital (PB) and valproate (VPA). Interictal EEG demonstrated left occipital spikes. When carbamazepine (CBZ) therapy was started, he developed very frequent (4-6/day) complex partial seizures (CPS) characterized on ictal EEG by focal right temporal lobe discharges. The seizure exacerbation, which was associated with development of nonepileptic, multifocal myoclonus, resolved 24 h after CBZ was discontinued. The exacerbation occurred with therapeutic CBZ serum levels, but may have been related to the toxic levels of carbamazepine-10, 11-epoxide (CBZE). 相似文献
3.
Zusammenfassung. Viele Hygienema?nahmen in Operationsabteilungen sind durch wissenschaftliche Untersuchungen nicht belegt. Die in dieser Arbeit
vom Nationalen Referenzzentrum für Krankenhaushygiene, das 1996 vom Bundesgesundheitsministerium eingerichtet wurde, zusammengestellten
Empfehlungen stützen sich auf die Ergebnisse wissenschaftlicher Untersuchungen und trennen so die unbedingt notwendigen von
den weniger bzw. nicht sinnvollen Ma?nahmen.
Summary. Many hygienic procedures performed in operation units are not supported by scientific investigations. The following recommendations by the National Reference Center for Hospital Epidemiology, founded by the German Ministry of Health in 1996, are based on the scientific literature and separate necessary from less necessary and unnecessary procedures.相似文献
4.
5.
Jason T. Siegel M.A. Eusebio M. Alvaro PhD. M.P.H. Michael Burgoon PhD. 《The Journal of adolescent health》2003,33(6):458-461
This research is supported in part by Arizona Disease Control and Research Commission (ADCRC), Grant #9904 (M. Burgoon, PI). This study assesses how adolescent nonsmokers, at-risk smokers, and smokers differ in perceptions of smoking harms, benefits, and safety. While small differences exist when comparing attitudes and knowledge concerning short- and long-term benefits of smoking, large differences arise when attitudes and knowledge concerning the short-term benefits and the safety of casual smoking are compared. 相似文献
6.
The tumor marker CA 15.3 was studied in 85 patients with liver cirrhosis. Nine patients (10.6%) had abnormal levels of CA 15.3 with the highest values in cases of Child's C patients. However, Child's classes were not significantly associated with the level of the antigen. We found significant correlations with some laboratory tests, especially IgA. All patients with an elevated CA 15.3 value also had abnormal levels of IgA, and multivariate analysis showed that IgA was the only independent factor associated with CA 15.3. Although IgA is a marker of alcoholic liver disease, other markers of alcoholism were not associated with CA 15.3. Cytolysis and cholestasis were not significantly associated with the CA 15.3 level, but liver dysfunction seemed to be involved. Liver disease does not substantially limit the usefulness of CA 15.3 in the cancer patient who also has liver cirrhosis, since both the percentage of abnormal values and the elevation of the serum levels are moderate in cirrhotic patients. 相似文献
7.
Elena del Olmo Carmen del Arco Alvaro Díaz Julio Pascual Guadalupe Mengod José M. Palacios Angel Pazos 《The European journal of neuroscience》1996,8(1):53-60
The pattern of pre- and postnatal appearance of 5-HT1D receptors throughout the different areas of the human brain was studied by quantitative in vitro autoradiography, using [125 I]GTI (serotonin O -carboxymethyl-glycyl-[125 I]tyrosinamide) as a ligand. The anatomical distribution of 5-HT1D receptors in neonatal, infant and children's brain was in good agreement with that observed in the adult, the basal ganglia and substantia nigra being the most intensely labelled areas. The development of these receptors throughout the human brain was mainly postnatal: low densities of [125 I]GTI binding sites were observed at the fetal/neonatal stage in most regions analyzed, in contrast with the high levels of labelling found in infant and children's brains. Indeed, in a number of regions, including the globus pallidus, substantia nigra and visual cortex, a peak of overexpression of 5-HT1D receptors was observed in the first decade of life. Such overexpression could support a regulatory role for 5-HT1D receptors in advanced periods of the CNS developmental process. Our results also indicate that the administration of drugs acting on 5-HT1D receptors during the early postnatal period of life could result in modifications of their properties, as these receptors are already functional in this period. 相似文献
8.
9.
M Angelico D Alvaro A Cantafora R Masella E Gaudio C Gandin S Ginanni Corradini F Ariosto O Riggio L Capocaccia 《Gastroenterology》1991,101(1):228-237
Lysophosphatidylcholine is a major metabolic product in the plasma and cellular turnover of phospholipids, with well-known membrane-toxic and proinflammatory properties. Because the liver plays a key role in plasma lysophosphatidylcholine removal and biotransformation and because virtually nothing is known of these processes in a diseased organ, the hepatobiliary metabolism of lysophosphatidylcholine was investigated in rats with carbon tetrachloride-induced liver cirrhosis. Twelve adult male Wistar rats with histologically confirmed cirrhosis and 8 control animals were fitted with jugular and biliary catheters and allowed to recover. The animals were kept under constant IV infusion of taurocholate (1 mumol/min). Two microcuries of sn-1[14C]palmitoyl-lysophosphatidylcholine was administered as a single bolus. The fate of the injected radioactivity, including removal from plasma, uptake, and subcellular location in the liver and molecular and aggregative forms, was studied by combined chromatographic and radiochemical methods. Major findings were (a) that lysophosphatidylcholine has a prolonged permanence in plasma of cirrhotic rats, due both to decreased hepatic clearance and to depressed conversion into phosphatidylcholine; (b) that the rate of lysophosphatidylcholine acylation is much slower in the cirrhotic than in the normal liver, both at the microsomal and at the cytosolic level; (c) that cytosolic lysophosphatidylcholine in the cirrhotic liver, but not in the normal liver, is predominantly non-protein bound; (d) that the strict molecular selectivity of lysophosphatidylcholine acylation observed in controls is partially lost in cirrhosis; and (e) that a consistent fraction of lysophosphatidylcholine is converted into triacylglycerols in cirrhotics but not in controls. These findings show a profound derangment of lysophosphatidylcholine handling and processing in the cirrhotic liver, which is of potential pathogenetic significance. 相似文献
10.
Prof. Dr. Dr. A. A. Fauser M. D. Ph. D. Dr. E. Lang Dr. G. Köchling Prof. Dr. F. D. Daschner 《Infection》1994,22(4):271-275
Summary A prospective, randomized clinical trial comparing combination therapy with ceftriaxone and teicoplanin versus ceftazidime and teicoplanin in the treatment of febrile episodes in neutropenic cancer patients and bone marrow transplant recipients was performed. One hundred and two patients were randomized, but two patients were considered unevaluable for efficacy, and three patients were withdrawn due to incorrect randomization. Of the remaining 97 patients, infection resolved without modification of therapy in 31/49 (63%) patients treated with ceftriaxone/teicoplanin versus 27/48 (56%) patients treated with ceftazidime/teicoplanin (P=0.48). Of all 97 patients treated therapy was modified in 18/49 (36%) with ceftriaxone/teicoplanin and 21/48 (43%) with ceftazidime/teicoplanin. Nineteen patients treated with ceftriaxone/teicoplanin received netilmicin and 21 patients treated with ceftazidime/teicoplanin also received netilmicin according to the study design (escalation therapy). When netilmicin was added infection resolved in 78% of patients treated with ceftriaxone/teicoplanin versus 84% of those treated with ceftazidime/teicoplanin. It was concluded that combination therapy with ceftriaxone/teicoplanin is an alternative to combination therapy with ceftazidime/teicoplanin, and has the advantage of once daily administration.
Antibiotische Therapie der febrilen Neutropenie von Tumor- und Knochenmarktransplantationspatienten. Eine randomisierte Studie mit Ceftriaxon und Teicoplanin im Vergleich mit Ceftazidim und Teicoplanin
Zusammenfassung In einer prospektiven, randomisierten klinischen Studie wurde die Kombinationstherapie mit Ceftriaxon und Teicoplanin gegen die Kombinationspartner Ceftazidim und Teicoplanin bei neutropenischen Patienten oder Patienten nach Knochenmarktransplantation verglichen. Insgesamt wurden 101 Patienten in die Studie eingebracht, davon waren 97 Patienten auswertbar. In der Ceftriaxon/Teicoplanin-Gruppe waren 63% der Patienten geheilt, gegenüber 56% der Patienten in der Ceftazidim/Teicoplanin-Gruppe. Dieses Ergebnis war ohne Modifikation der Studien-Medikamente erreicht worden. Bei 18 von 49 Patienten in der Ceftriaxon/Teicoplanin-Gruppe und 21 von 48 Patienten in der Ceftazidim/Teicoplanin-Gruppe wurde von der Studienmedikation abgegangen und zusätzlich Netilmicin (Eskalationstherapie) gegeben. Durch die zusätzliche Gabe von Netilmicin waren 78% der Patienten in der Ceftriaxon/Teicoplanin-Gruppe und 84% in der Ceftazidim/Teicoplanin-Gruppe geheilt. Diese Daten deuten darauf hin, daß die Kombinationstherapie mit Ceftriaxon/Teicoplanin eine Alternative zur Kombinationstherapie mit Ceftazidim und Teicoplanin darstellt, zumal die Gabe von Ceftriaxon und Teicoplanin den Vorteil hat, daß diese Medikamente nur einmal pro Tag gegeben werden müssen.相似文献